Walleye Capital’s Gyre Therapeutics GYRE Stock Holding History

Walleye Capital’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,403	Closed	-$167	–	2188
2021 Q3	$167	Buy	+5,403	New	+$178K	﹤0.01%	1227
2018 Q3	$489K	Buy	+6,054	New	+$480K	0.23%	128

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Walleye Capital's GYRE Position: Q4 2021 in Review

Walleye Capital sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 5,403 shares — an estimated $167 sold.

Walleye Capital first reported a position in GYRE in Q3 2018 and held it in 2 quarters. The position peaked at $489K in Q3 2018. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

Walleye Capital reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
Walleye Capital sold 5,403 Gyre Therapeutics shares in Q4 2021, an estimated $167.
Walleye Capital first reported a position in Gyre Therapeutics in Q3 2018 and held it in 2 quarters.
Walleye Capital's Gyre Therapeutics position peaked at $489K in Q3 2018.
51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on Walleye Capital's 13F filing for Q4 2021, filed 3 Mar 2022.